304 related articles for article (PubMed ID: 23616632)
1. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
[TBL] [Abstract][Full Text] [Related]
3. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.
Li Z; Bonekamp S; Halappa VG; Corona-Villalobos CP; Pawlik T; Bhagat N; Reyes D; Lai H; Geschwind JF; Kamel IR
Radiology; 2012 Jul; 264(1):97-109. PubMed ID: 22627602
[TBL] [Abstract][Full Text] [Related]
4. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response.
Halappa VG; Bonekamp S; Corona-Villalobos CP; Li Z; Mensa M; Reyes D; Eng J; Bhagat N; Pawlik TM; Geschwind JF; Kamel IR
Radiology; 2012 Jul; 264(1):285-94. PubMed ID: 22627601
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
8. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
Chapiro J; Duran R; Lin M; Schernthaner RE; Wang Z; Gorodetski B; Geschwind JF
Radiology; 2015 May; 275(2):438-47. PubMed ID: 25531387
[TBL] [Abstract][Full Text] [Related]
9. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
11. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
12. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.
Bonekamp S; Li Z; Geschwind JF; Halappa VG; Corona-Villalobos CP; Reyes D; Pawlik TM; Bonekamp D; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):420-30. PubMed ID: 23616631
[TBL] [Abstract][Full Text] [Related]
13. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
[TBL] [Abstract][Full Text] [Related]
15. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
[TBL] [Abstract][Full Text] [Related]
16. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?
Georgiades C; Geschwind JF; Harrison N; Hines-Peralta A; Liapi E; Hong K; Wu Z; Kamel I; Frangakis C
Radiology; 2012 Oct; 265(1):115-23. PubMed ID: 22891361
[TBL] [Abstract][Full Text] [Related]
17. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
[TBL] [Abstract][Full Text] [Related]
19. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
Kim CJ; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MJ
Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
[TBL] [Abstract][Full Text] [Related]
20. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
Corona-Villalobos CP; Halappa VG; Geschwind JF; Bonekamp S; Reyes D; Cosgrove D; Pawlik TM; Kamel IR
Eur Radiol; 2015 Feb; 25(2):380-90. PubMed ID: 25226843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
